IDX184

IDX184 is a potent and orally bioavailable inhibitor of HCV replication. IDX184 potently inhibits HCV polymerase (IC50=0.31 μM, Ki=52.3 nM) [1][2].

Product Specifications

CAS Number

[1036915-08-8]

UNSPSC

12352005

Target

HCV; HCV Protease

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/idx184.html

Purity

99.80

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

C[C@]([C@](O[C@@H]1CO[P](NCC2=CC=CC=C2)(OCCSC(C(C)(C)CO)=O)=O)([H])N3C(NC(N)=NC4=O)=C4N=C3)([C@@H]1O)O

Molecular Formula

C25H35N6O9PS

Molecular Weight

626.62

References & Citations

[1]Xiao-Jian Zhou , et al. Safety and Pharmacokinetics of IDX184, a Liver-Targeted Nucleotide Polymerase Inhibitor of Hepatitis C Virus, in Healthy Subjects. Antimicrob Agents Chemother. 2011 Jan;55 (1) :76-81.|[2]IN VITRO ANTIVIRAL ACTIVITY AND PHARMACOLOGY OF IDX184, A NOVEL AND POTENT INHIBITOR OF HCV REPLICATION.